APA (7th ed.) Citation

CL, M., AC, H., HH, S., K, B., A, S., D, V., . . . TR, G. (2025). ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(6), 716. https://doi.org/10.1200/JCO.24.01034

Chicago Style (17th ed.) Citation

CL, Moertel, et al. "ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 6 (2025): 716. https://doi.org/10.1200/JCO.24.01034.

MLA (9th ed.) Citation

CL, Moertel, et al. "ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 6, 2025, p. 716, https://doi.org/10.1200/JCO.24.01034.